[{"address1": "3020 Carrington Mill Blvd.", "address2": "Suite 475", "city": "Morrisville", "state": "NC", "zip": "27560", "country": "United States", "phone": "212 554 4484", "fax": "212 554 4531", "website": "https://www.tgtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.", "fullTimeEmployees": 374, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael S. Weiss Esq., J.D.", "age": 58, "title": "Chairman, CEO & President", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 1970938, "exercisedValue": 0, "unexercisedValue": 26229992}, {"maxAge": 1, "name": "Mr. Sean A. Power CPA", "age": 42, "title": "CFO, Corporate Secretary & Treasurer", "yearBorn": 1982, "fiscalYear": 2024, "totalPay": 780600, "exercisedValue": 0, "unexercisedValue": 8840500}, {"maxAge": 1, "name": "Ms. Jenna  Bosco", "title": "Senior Vice President of Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Waldman", "title": "Chief Commercialization Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 3, "overallRisk": 10, "governanceEpochDate": 1764547200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 29.93, "open": 29.96, "dayLow": 29.79, "dayHigh": 31.26, "regularMarketPreviousClose": 29.93, "regularMarketOpen": 29.96, "regularMarketDayLow": 29.79, "regularMarketDayHigh": 31.26, "payoutRatio": 0.0, "beta": 2.013, "trailingPE": 11.184115, "forwardPE": 16.085567, "volume": 2447239, "regularMarketVolume": 2447239, "averageVolume": 1797137, "averageVolume10days": 1519020, "averageDailyVolume10Day": 1519020, "bid": 26.8, "ask": 35.4, "bidSize": 1, "askSize": 1, "marketCap": 4918367744, "fiftyTwoWeekLow": 25.28, "fiftyTwoWeekHigh": 46.48, "allTimeHigh": 233.4375, "allTimeLow": 0.95625, "priceToSalesTrailing12Months": 9.246825, "fiftyDayAverage": 32.4503, "twoHundredDayAverage": 34.8853, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 4652167168, "profitMargins": 0.84128, "floatShares": 140386483, "sharesOutstanding": 158759451, "sharesShort": 25094516, "sharesShortPriorMonth": 23579473, "sharesShortPreviousMonthDate": 1761868800, "dateShortInterest": 1764288000, "sharesPercentSharesOut": 0.15810001, "heldPercentInsiders": 0.06784, "heldPercentInstitutions": 0.63847, "shortRatio": 11.55, "shortPercentOfFloat": 0.2067, "impliedSharesOutstanding": 158759451, "bookValue": 4.256, "priceToBook": 7.279135, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "earningsQuarterlyGrowth": 99.746, "netIncomeToCommon": 447472992, "trailingEps": 2.77, "forwardEps": 1.92595, "lastSplitFactor": "100:5625", "lastSplitDate": 1335744000, "enterpriseToRevenue": 8.746, "enterpriseToEbitda": 45.243, "52WeekChange": -0.03967762, "SandP52WeekChange": 0.14402747, "quoteType": "EQUITY", "currentPrice": 30.98, "targetHighPrice": 60.0, "targetLowPrice": 13.0, "targetMeanPrice": 44.28571, "targetMedianPrice": 49.0, "recommendationKey": "none", "numberOfAnalystOpinions": 7, "totalCash": 131582000, "totalCashPerShare": 0.9, "ebitda": 102826000, "totalDebt": 254540000, "quickRatio": 2.532, "currentRatio": 3.825, "totalRevenue": 531897984, "debtToEquity": 41.919, "revenuePerShare": 3.643, "returnOnAssets": 0.07975, "returnOnEquity": 1.11956, "grossProfits": 453927008, "freeCashflow": -94664496, "operatingCashflow": -70073000, "earningsGrowth": 120.5, "revenueGrowth": 0.928, "grossMargins": 0.85341, "ebitdaMargins": 0.19332, "operatingMargins": 0.18159, "financialCurrency": "USD", "symbol": "TGTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "fiftyTwoWeekLowChange": 5.699999, "fiftyTwoWeekLowChangePercent": 0.22547463, "fiftyTwoWeekRange": "25.28 - 46.48", "fiftyTwoWeekHighChange": -15.5, "fiftyTwoWeekHighChangePercent": -0.33347678, "fiftyTwoWeekChangePercent": -3.967762, "earningsTimestamp": 1762176600, "earningsTimestampStart": 1762176600, "earningsTimestampEnd": 1762176600, "earningsCallTimestampStart": 1762176600, "earningsCallTimestampEnd": 1762176600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 2.77, "epsForward": 1.92595, "epsCurrentYear": 2.87476, "priceEpsCurrentYear": 10.776552, "shortName": "TG Therapeutics, Inc.", "longName": "TG Therapeutics, Inc.", "regularMarketChangePercent": 3.50818, "regularMarketPrice": 30.98, "fiftyDayAverageChange": -1.4702988, "fiftyDayAverageChangePercent": -0.045309253, "twoHundredDayAverageChange": -3.9053001, "twoHundredDayAverageChangePercent": -0.11194687, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1766191177, "regularMarketTime": 1766178000, "exchange": "NCM", "messageBoardId": "finmb_143627354", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1272893400000, "postMarketChangePercent": -0.22595124, "postMarketPrice": 30.91, "postMarketChange": -0.069999695, "regularMarketChange": 1.05, "regularMarketDayRange": "29.79 - 31.26", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1797137, "displayName": "TG Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-12-20"}]